DexCom (NASDAQ:DXCM) Releases Earnings Results

DexCom (NASDAQ:DXCM) issued its quarterly earnings data on Thursday. The medical device company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.68 by $0.05, FiscalAI reports. The firm had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 36.96%. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 earnings per share.

Here are the key takeaways from DexCom’s conference call:

• Q3 revenue rose 11% to $1.34 billion, with U.S. revenue up 14% and continued market-share gains. Management said new patient starts were near record levels and raised full-year revenue guidance to $5.20–$5.25 billion, implying 12%–13% growth.
• Gross margin expanded to 65.1% from 61.3% a year ago, while operating and adjusted EBITDA margins also improved. Dexcom generated more than $900 million in free cash flow through nine months, completed a $1 billion 2026 buyback, and authorized another $1 billion repurchase.
• The company highlighted strong clinical support for broader CGM reimbursement after its CONNECT trial showed a 1.6% A1C reduction in non-insulin-using type 2 patients and was published in the New England Journal of Medicine. Dexcom still expects a CMS coverage decision this year, with potential implementation around mid-2027.
• G7 15 Day adoption is tracking toward nearly 50% of the U.S. customer base by year-end, with improved sensor survivability and positive customer feedback. International launches are beginning in Canada, Japan is targeted for early 2027, and Ireland has started commercial production to expand global capacity.
• International growth slowed to 5% as Dexcom lapped prior reimbursement wins, although management expects normalization in early 2027. A CVS/PBM formulary change could raise out-of-pocket costs for some patients, even though management said the affected PBM represents less than 4% of U.S. revenue and should have limited financial impact next year.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $82.29 on Friday. DexCom has a 1 year low of $54.11 and a 1 year high of $92.59. The stock has a market capitalization of $31.05 billion, a P/E ratio of 32.27, a P/E/G ratio of 1.34 and a beta of 1.48. The company’s 50-day moving average is $85.82 and its 200 day moving average is $74.65. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom News Summary

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

Insiders Place Their Bets

In related news, EVP Jereme Sylvain sold 3,638 shares of DexCom stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president directly owned 146,828 shares in the company, valued at $12,226,367.56. The trade was a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of DexCom stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the sale, the director owned 48,852 shares in the company, valued at $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 24,822 shares of company stock valued at $2,090,833 over the last ninety days. 0.28% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on DXCM shares. Argus upped their price target on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Barclays lifted their price objective on DexCom from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday. BTIG Research boosted their target price on DexCom from $90.00 to $96.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Mizuho set a $100.00 target price on DexCom in a report on Tuesday, October 13th. Finally, Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a report on Sunday, September 6th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $92.91.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.